DK1896020T3 - SKI 606 som src-kinase-inhibitor til behandling af osteolytiske læsioner - Google Patents

SKI 606 som src-kinase-inhibitor til behandling af osteolytiske læsioner

Info

Publication number
DK1896020T3
DK1896020T3 DK06773373.3T DK06773373T DK1896020T3 DK 1896020 T3 DK1896020 T3 DK 1896020T3 DK 06773373 T DK06773373 T DK 06773373T DK 1896020 T3 DK1896020 T3 DK 1896020T3
Authority
DK
Denmark
Prior art keywords
ski
treatment
kinase inhibitor
src kinase
osteolytic lesions
Prior art date
Application number
DK06773373.3T
Other languages
English (en)
Inventor
Ann Poblenz
Bryant G Darnay
Janet E Price
Moshe Talpaz
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Application granted granted Critical
Publication of DK1896020T3 publication Critical patent/DK1896020T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
DK06773373.3T 2005-06-17 2006-06-16 SKI 606 som src-kinase-inhibitor til behandling af osteolytiske læsioner DK1896020T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69193305P 2005-06-17 2005-06-17
PCT/US2006/023529 WO2006138590A1 (en) 2005-06-17 2006-06-16 Inhibition of osteolytic lesions by src kinase inhibitors

Publications (1)

Publication Number Publication Date
DK1896020T3 true DK1896020T3 (da) 2014-10-27

Family

ID=37570781

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06773373.3T DK1896020T3 (da) 2005-06-17 2006-06-16 SKI 606 som src-kinase-inhibitor til behandling af osteolytiske læsioner

Country Status (18)

Country Link
US (1) US7468379B2 (da)
EP (1) EP1896020B1 (da)
JP (1) JP5121706B2 (da)
KR (2) KR101385488B1 (da)
CN (2) CN101242835A (da)
AU (1) AU2006259243B2 (da)
BR (1) BRPI0613146B8 (da)
CA (1) CA2612333C (da)
DK (1) DK1896020T3 (da)
ES (1) ES2509875T3 (da)
HK (1) HK1116087A1 (da)
IL (1) IL188146A (da)
MX (1) MX2007016230A (da)
NZ (1) NZ564507A (da)
PL (1) PL1896020T3 (da)
PT (1) PT1896020E (da)
SI (1) SI1896020T1 (da)
WO (1) WO2006138590A1 (da)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109953986A (zh) * 2019-04-04 2019-07-02 泉州师范学院 一种小分子抑制剂azin53及其在制药中的应用
WO2021245677A1 (en) * 2020-06-05 2021-12-09 Digestix Bioscience Inc. Compositions and methods for treating dysplastic and early-stage neoplastic conditions
WO2024054793A1 (en) * 2022-09-09 2024-03-14 University Of Rochester Inhibition of efferocytosis as a treatment to prevent bone loss and increase bone density and strength

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4870287A (en) 1988-03-03 1989-09-26 Loma Linda University Medical Center Multi-station proton beam therapy system
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
US5760395A (en) 1996-04-18 1998-06-02 Universities Research Assoc., Inc. Method and apparatus for laser-controlled proton beam radiology
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
JPH10287679A (ja) * 1997-04-11 1998-10-27 Takeda Chem Ind Ltd Ｔａｎ−２４８３関連化合物、その製造法および用途
IL150059A0 (en) * 1999-12-17 2002-12-01 Ariad Pharma Inc Novel heterocycles
AU2441701A (en) * 1999-12-17 2001-06-25 Ariad Pharmaceuticals, Inc. Purine derivatives
US20030045480A1 (en) * 2001-07-09 2003-03-06 Pavel Safar Method of treating hyperresorptive bone disorders
TWI275390B (en) 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
JP2005008581A (ja) * 2003-06-20 2005-01-13 Kissei Pharmaceut Co Ltd 新規なピラゾロ［１，５−ａ］ピリミジン誘導体、それを含有する医薬組成物およびそれらの用途
JP2005089352A (ja) * 2003-09-16 2005-04-07 Kissei Pharmaceut Co Ltd 新規なイミダゾ［１，５−ａ］ピラジン誘導体、それを含有する医薬組成物およびそれらの用途
CN1874776A (zh) 2003-11-06 2006-12-06 惠氏公司 治疗慢性骨髓性白血病(cml)的4－苯胺基－3－喹啉腈

Also Published As

Publication number Publication date
KR20080030025A (ko) 2008-04-03
PT1896020E (pt) 2014-10-28
SI1896020T1 (sl) 2014-11-28
CA2612333A1 (en) 2006-12-28
US20070004748A1 (en) 2007-01-04
BRPI0613146B1 (pt) 2020-08-11
JP5121706B2 (ja) 2013-01-16
EP1896020A1 (en) 2008-03-12
NZ564507A (en) 2010-12-24
WO2006138590A1 (en) 2006-12-28
JP2008543870A (ja) 2008-12-04
HK1116087A1 (en) 2008-12-19
IL188146A0 (en) 2008-06-05
PL1896020T3 (pl) 2015-02-27
US7468379B2 (en) 2008-12-23
MX2007016230A (es) 2008-03-06
EP1896020A4 (en) 2010-11-24
CA2612333C (en) 2013-12-17
CN101242835A (zh) 2008-08-13
ES2509875T3 (es) 2014-10-20
AU2006259243A1 (en) 2006-12-28
BRPI0613146B8 (pt) 2021-05-25
KR101385488B1 (ko) 2014-04-15
EP1896020B1 (en) 2014-08-20
CN103705517A (zh) 2014-04-09
IL188146A (en) 2016-04-21
BRPI0613146A2 (pt) 2010-12-21
KR20140036336A (ko) 2014-03-25
AU2006259243B2 (en) 2011-04-21

Similar Documents

Publication Publication Date Title
HK1133641A1 (zh) 激酶抑製劑化合物
IL183938A0 (en) Amino - imidazolones for the inhibition of ?? - becretase
NO20082517L (no) Aminopyrimidiner anvendelige som kinaseinhibitorer
DK1711481T4 (da) Krystallinsk monohydrat som kinaseinhibitorer
DK1737461T3 (da) Carbolin-derivater til inhibering af angiogenese
ES2527409T4 (es) Formulaciones de inhibidores de DPP IV
DK1585749T3 (da) Diazepinoindol-derivater som kinaseinhibitorer
DK1948678T3 (da) Forbindelser til enzyminhibering
DK1699797T3 (da) Pyrrolotriazinforbindelser som kinasehæmmere
DK1937671T3 (da) Benzimidazolthiophenforbindelser som PLK-inhibitorer
DK1907373T3 (da) Fremgangsmåder til fremstillingen af 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindolin-1,3-dionforbindelser
DK1586319T3 (da) Thiadiazolidinoner som GSK-3-inhibitorer
DK1926722T3 (da) Substituerede benzimidazoler som kinaseinhibitorer
DK1789041T3 (da) Aryl-pyridinderivater som 11-beta-HSD1-inhibitorer
IL180495A0 (en) Benzyltriazolone compounds as nin-nucleoside reverse transcriptase inhibitors
HK1114380A1 (en) Pyrrolopyrazoles as kinase inhibitors
DK1797042T3 (da) Indozolonderivater som 11B-HSD1-inhibitorer
IL190078A0 (en) Kinase inhibitors
IL197381A0 (en) Kinase inhibitor
DK1948176T3 (da) Diarylurinstoffer til behandling af pulmonær hypertension
DK1943243T3 (da) Kinase-inhibitorer
ATE433449T1 (de) Kinaseinhibitoren
DK1847524T3 (da) Terphenylderivater til behandling af Alzheimers sygdom
ATE520664T1 (de) Tyrosinkinase-hemmer
DK1896020T3 (da) SKI 606 som src-kinase-inhibitor til behandling af osteolytiske læsioner